References
Margonis GA, Buettner S, Andreatos N, et al. Prognostic factors change over time after hepatectomy for colorectal liver metastases: a multi-institutional, international analysis of 1099 patients. Ann Surg. 2019;269(6):1129–37. https://doi.org/10.1097/SLA.0000000000002664.
Ayez N, van der Stok EP, Grünhagen DJ, et al. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur J Surg Oncol. 2015;41(7):859–67. https://doi.org/10.1016/j.ejso.2015.04.012.
Wang XY, Zhang R, Han JH, et al. Early circulating tumor DNA dynamics predict neoadjuvant therapy response and recurrence in colorectal liver metastases: a prospective study. Ann Surg Oncol. 2023;30(8):5252–63. https://doi.org/10.1245/s10434-023-13604-2.
Deveson IW, Gong B, Lai K, et al. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 2021;39(9):1115–28. https://doi.org/10.1038/s41587-021-00857-z.
Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clinical Chemistry. 2015;61(1):112–23. https://doi.org/10.1373/clinchem.2014.222679.
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312. https://doi.org/10.1038/s41571-020-00457-x.
Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–87. https://doi.org/10.1056/NEJMoa1409405.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The authors declare that they have no conflict of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Surendran, A.K., Mavani, P.T. & Vijayakumar, C. Circulating Tumor DNA Dynamics: A New Approach in Revolutionizing Cancer Management. Ann Surg Oncol 31, 163–164 (2024). https://doi.org/10.1245/s10434-023-14452-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-14452-w